Daniela Diamanti

An exploratory double‐blind, randomized clinical trial with selisistat, a <scp>SirT1</scp> inhibitor, in patients with <scp>H</scp>untington's disease

Sigurd D. Süßmuth, Salman Haider, G. Bernhard Landwehrmeyer et al. · British Journal of Clinical Pharmacology · 2014 · 164 citations · Full text

Medicine, Neurology, Pharmacology +17

siRNA screen identifies QPCT as a druggable target for Huntington's disease

María Jiménez-Sánchez, Wun Lam, Michael Hannus et al. · Nature Chemical Biology · 2015 · 96 citations · Full text

Life Sciences, Genetics, Molecular Biology +13

Safety, pharmacokinetics, pharmacogenomics and <scp>QT</scp> concentration−effect modelling of the <scp>SirT1</scp> inhibitor selisistat in healthy volunteers

Göran Westerberg, Joseph Chiesa, Claus A. Andersen et al. · British Journal of Clinical Pharmacology · 2014 · 58 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +11

Increased expression of the oligopeptidase THOP1 is a neuroprotective response to Aβ toxicity

Giuseppe Pollio, Jeroen J.M. Hoozemans, Claus A. Andersen et al. · Neurobiology of Disease · 2008 · 47 citations · Full text

Life Sciences, Neurobiology, Neuroscience +16

Functional Characterization of a Small-Molecule Inhibitor of the DKK1-LRP6 Interaction

Sara Iozzi, Rosaria Remelli, Barbara Lelli et al. · ISRN Molecular Biology · 2012 · 34 citations · Full text

Life Sciences, Medicinal Chemistry, Molecular Biology +17